Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 8,158 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Completed Not applicable Interventional

Comparison of Apidra to Regular Insulin in Hospitalized Patients

NCT00528918
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Glulisine (Apidra)
Drug
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 30, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional Results available

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

NCT01953926
View directory record Official record
Conditions
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Interventions
Neratinib, Fulvestrant, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 30, 2026, 8:16 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

NCT04436640
View directory record Official record
Conditions
Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 8:16 PM EDT
Completed No phase listed Observational

Restore EF Observational Study

NCT04648306
View directory record Official record
Conditions
Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
Interventions
Prophylactic Impella support for a non-emergent PCI
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 30, 2026, 8:16 PM EDT
Terminated Phase 3 Interventional

Right to Left Cardiac Shunt Detection

NCT01773252
View directory record Official record
Conditions
Right to Left Shunt, Patent Foramen Ovale, Atrial Septal Defect
Interventions
Flow Detection System
Device
Lead sponsor
Cardiox Corporation
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 30, 2026, 8:16 PM EDT
Active, not recruiting No phase listed Observational

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions
Faricimab, Port Delivery System with Ranibizumab
Drug · Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

Aztreonam Lysine for Pseudomonas Infection Eradication Study

NCT01375049
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 30, 2026, 8:16 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.

NCT07779408
View directory record Official record
Conditions
Healthy Volunteers, Influenza
Interventions
Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, without adjuvant
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
16
States / cities
Tempe, Arizona • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 8:16 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

NCT03843125
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 30, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

NCT01722318
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
99
States / cities
Birmingham, Alabama • Dothan, Alabama • Glendale, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 30, 2026, 8:16 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

NCT00402363
View directory record Official record
Conditions
Fibrillation, Atrial
Interventions
omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
178
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 149 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 30, 2026, 8:16 PM EDT
Not listed No phase listed Observational

Multi-Institutional Registry for Prostate Cancer Radiosurgery

NCT01226004
View directory record Official record
Conditions
Prostate Cancer Early Risk Treated by Radiosurgery, Prostate Cancer Intermediate Risk Treated by Radiosurgery
Interventions
Not listed
Lead sponsor
RPCR, Inc.
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
44
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 30, 2026, 8:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints

NCT00292552
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Novel endpoint determination
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
2,747 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
20
States / cities
Phoenix, Arizona • Rancho Mirage, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 30, 2026, 8:16 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

NCT07129252
View directory record Official record
Conditions
SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Interventions
CRN09682
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Duarte, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 8:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

NCT00098748
View directory record Official record
Conditions
HIV Infections
Interventions
Optimized Background Therapy (OBT), maraviroc (UK-427,857)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Oct 30, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional

Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease

NCT05079126
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Trans Sodium Crocetinate, Placebo
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
30 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 30, 2026, 8:16 PM EDT
Terminated Phase 3 Interventional

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

NCT00332826
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions
Technosphere Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 4, 2012 · Synced Oct 30, 2026, 8:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

NCT03766685
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 30, 2026, 8:16 PM EDT
Completed Not applicable Interventional Results available

A Safety and Effectiveness Trial of Spinal Cord Stimulation of the Dorsal Root Ganglion for Chronic Lower Limb Pain

NCT01923285
View directory record Official record
Conditions
Chronic Lower Limb Pain
Interventions
AXIUM Neurostimulator System, Control Spinal Cord Stimulation Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
22 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Aptos, California • Carlsbad, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 30, 2026, 8:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Collaborative Surgical Proficiency Initiative

NCT01050335
View directory record Official record
Conditions
Surgical Proficiency
Interventions
Simuvision Simulator
Behavioral
Lead sponsor
Phoenix Integrated Surgical Residency
Other
Eligibility
23 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 30, 2026, 8:16 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

NCT01313676
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
16,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
506
States / cities
Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 30, 2026, 8:16 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 11 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 8:16 PM EDT
Active, not recruiting Phase 1 Interventional

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

NCT04184050
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
Interventions
MK-4002
Drug
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 30, 2026, 8:16 PM EDT